We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04606381
Recruitment Status : Recruiting
First Posted : October 28, 2020
Last Update Posted : May 6, 2023
Information provided by (Responsible Party):
Janssen Research & Development, LLC

Brief Summary:
The purpose of this study is to assess the feasibility of subcutaneous (SC) administration of amivantamab based on safety and pharmacokinetics and determine a dose, dose regimen and formulation for amivantamab SC delivery.

Condition or disease Intervention/treatment Phase
Advanced Solid Malignancies Drug: Ami-LC-MD Drug: Ami-LC Drug: Ami-HC Drug: Ami-HC-CF Drug: Lazertinib Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 196 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab, a Human Bispecific EGFR and cMet Antibody for the Treatment of Advanced Solid Malignancies
Actual Study Start Date : November 10, 2020
Estimated Primary Completion Date : October 10, 2023
Estimated Study Completion Date : October 2, 2024

Resource links provided by the National Library of Medicine

Drug Information available for: Amivantamab

Arm Intervention/treatment
Experimental: Part 1: Ami-LC-MD and Ami-LC
Participants in cohort 1a will receive amivantamab admixed with rHuPH20 (Ami-LC-MD) subcutaneous (SC) infusion and participants in cohort 1b will receive amivantamab (Ami-LC) SC infusion.
Drug: Ami-LC-MD
Participants will receive amivantamab admixed with rHuPH20 SC infusion.

Drug: Ami-LC
Participants will receive amivantamab SC infusion.

Experimental: Part 2: Ami-HC and Ami-HC-CF
Participants will receive SC infusion of newly developed high concentration amivantamab (Ami-HC) or amivantamab co-formulated with rHuPH20 (Ami-HC-CF).
Drug: Ami-HC
Participants will receive amivantamab SC infusion.

Drug: Ami-HC-CF
Participants will receive amivantamab co-formulated with rHuPH20 as SC infusion.

Experimental: Part 3: Ami-HC-CF + Lazertinib and Ami-HC+ Lazertinib
Participants will receive SC infusion of either Ami-HC-CF or Ami-HC in combination with lazertinib tablet.
Drug: Ami-HC
Participants will receive amivantamab SC infusion.

Drug: Ami-HC-CF
Participants will receive amivantamab co-formulated with rHuPH20 as SC infusion.

Drug: Lazertinib
Participants will receive lazertinib orally as a film-coated tablet.
Other Names:
  • JNJ-73841937
  • YH25448

Primary Outcome Measures :
  1. Observed Amivantamab Serum Concentration Immediately Prior to the Next Dose Administration (Ctrough) [ Time Frame: Up to Day 29 ]
    Ctrough is the observed amivantamab serum concentration immediately prior to the next drug administration.

  2. Amivantamab Steady-state Area Under the Curve (AUCss) [ Time Frame: Cycle 4 (28 days) ]
    AUCss is defined as the area under the curve for amivantamab at steady state.

  3. Number of Participants with Adverse Event (AE) [ Time Frame: Up to 4 years 1 month ]
    An adverse event is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the drug. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.

  4. Number of Participants with Dose Limiting Toxicity (DLT) [ Time Frame: Up to Day 28 ]
    Number of participants with DLT will be assessed.

  5. Number of Participants with Clinical Laboratory Abnormalities [ Time Frame: Up to 4 years 1 month ]
    Number of participants with clinical laboratory (hematology, clinical chemistry, and urinalysis) abnormalities will be assessed.

Secondary Outcome Measures :
  1. Number of Participants with Anti-amivantamab and Anti-rHuPH20 antibodies [ Time Frame: Up to 4 years 1 month ]
    Number of participants with anti-amivantamab and anti-rHuPH20 antibodies will be assessed.

  2. Part 3: Plasma Concentration of Lazertinib [ Time Frame: Up to 4 years 1 month ]
    Plasma samples will be analyzed to determine concentrations of lazertinib using a validated method.

  3. Epidermal Growth Factor Receptor (EGFR) Concentrations [ Time Frame: Up to 4 years 1 month ]
    EGRF concentrations markers will be assessed.

  4. Mesenchymal-Epidermal Transition Tyrosine Kinase Receptor/Hepatocyte Growth Factor Receptor (cMET) Markers [ Time Frame: Up to 4 years 1 month ]
    cMET markers will be analyzed.

  5. Overall Response Rate (ORR) [ Time Frame: Up to 4 years 1 month ]
    ORR defined as the proportion of participants with partial response (PR) or better according to Response Criteria in Solid Tumors (RECIST) v1.1.

  6. Part 2: Maximum Amivantamab Dosing Interval Between Time Zero to Steady State [ Time Frame: Up to 4 years 1 month ]
    Maximum amivantamab dosing interval Between time zero to steady state will be assessed.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Part 1 and Part 2: Participant must have histologically or cytologically confirmed solid malignancy that is metastatic or unresectable and which may derive benefit from epidermal growth factor receptor (EGFR) or mesenchymal-epidermal transition tyrosine kinase receptor/hepatocyte growth factor receptor (cMet) directed therapy. Eligible tumor types include non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), hepatocellular cancer (HCC), colorectal cancer (CRC), renal cell cancer (RCC), medullary thyroid cancer (MTC), gastroesophageal cancer (GEC), mesothelioma, breast cancer (BC) and ovarian cancer (OC). Participants must have either progressed after prior standard of care therapy for metastatic disease, be ineligible for, or have refused all other currently available therapeutic options. In cases where participants refuse currently available therapeutic options, this must be documented in the study records; Part 3: Participants with histologically or cytologically confirmed NSCLC with previously identified EGFR mutation (identified locally in a Clinical Laboratory Improvement Amendments [CLIA]-certified laboratory [or equivalent]) that is metastatic or unresectable and have progressed on or after at least one line of standard of care systemic treatment for metastatic disease. Required prior therapy includes an approved anti-EGFR tyrosine kinase inhibitor (TKI), or in the case of EGFR exon 20 insertion mutation disease, platinum-based chemotherapy. A participant who has refused all other currently available therapeutic options is allowed to enroll and must be documented in the study records
  • Participant must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • A woman of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) at Screening and a negative urine or serum pregnancy test within 24 hours before the first dose of study drug
  • A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 6 months after receiving the last dose of study drug
  • A man who is sexually active with a woman of childbearing potential must agree to use a condom and his partner must also be practicing a highly effective method of contraception (that is, established use of oral, injected or implanted hormonal methods of contraception; placement of an Intrauterine device [IUD] or Intrauterine system [IUS])

Exclusion criteria:

  • Participant has uncontrolled inter-current illness, including but not limited to poorly controlled hypertension or diabetes, ongoing or active systemic infection (that is, has discontinued all antibiotics for at least one week prior to first dose of study drug), diagnosed or suspected viral infection (except Human immunodeficiency virus [HIV] positive participants with 1 or more of the following: a) not receiving highly active antiretroviral therapy; b) a change in antiretroviral therapy within 6 months of the start of screening; c) cluster of differentiation 4 (CD4)+ T-cell count less than [<]350 per cubic millimeters [mm^3] at screening; d) an acquired immunodeficiency syndrome-defining opportunistic infection within 6 months of the start of screening), or psychiatric illness/social situation that would limit compliance with study requirements, including ability to self-care for anticipated toxicities [that is. rash or paronychia]. Participants with medical conditions requiring chronic continuous oxygen therapy are excluded
  • Participant has had prior chemotherapy, targeted cancer therapy, or treatment with an investigational anti-cancer agent within 2 weeks or 4 half-lives, whichever is longer, before the first administration of study drug; or participant has received prior immunotherapy within 6 weeks before the first administration of study drug. For agents with long half-lives, the maximum required time since last dose is 4 weeks. Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less, (except for alopecia [any grade], Grade less than or equal to [<=] 2 peripheral neuropathy, and Grade less than [<] 2 hypothyroidism stable on hormone replacement). Autoimmune toxicities from previous immunotherapy must be fully resolved to baseline levels
  • Participants with untreated brain metastases. Participants with locally treated metastases that are clinically stable and asymptomatic for at least 2 weeks and who are off or receiving low-dose corticosteroid treatment (<=10 milligrams [mg] prednisone or equivalent) for at least 2 weeks prior to study treatment are eligible
  • Participant has an active malignancy other than the disease under study requiring treatment
  • Participant has leptomeningeal disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04606381

Layout table for location contacts
Contact: Study Contact 844-434-4210 Participate-In-This-Study@its.jnj.com

Layout table for location information
United States, California
Cedars Sinai Medical Center Recruiting
West Hollywood, California, United States, 90048
United States, Indiana
Community Health Network Recruiting
Indianapolis, Indiana, United States, 46256
United States, New York
Langone Health at NYC University, NYU School of Medicine Recruiting
New York, New York, United States, 10016
United States, Oregon
Providence Portland Medical Center Recruiting
Portland, Oregon, United States, 97213
United States, Tennessee
Sarah Cannon Research Institute Recruiting
Nashville, Tennessee, United States, 37203
Canada, Ontario
University Health Network Recruiting
Toronto, Ontario, Canada, M5G 2M9
Korea, Republic of
Chungbuk National University Hospital Recruiting
Cheongju-si, Korea, Republic of, 28644
Seoul National University Bundang Hospital Recruiting
Gyeonggi-do, Korea, Republic of, 13620
Severance Hospital, Yonsei University Health System Recruiting
Seoul, Korea, Republic of, 03722
Samsung Medical Center Recruiting
Seoul, Korea, Republic of, 06351
United Kingdom
The Christie Nhs Foundation Trust Recruiting
Manchester, United Kingdom, M20 4BX
Royal Marsden Hospital Recruiting
Sutton, United Kingdom, SM2 5PT
Sponsors and Collaborators
Janssen Research & Development, LLC
Layout table for investigator information
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC
Layout table for additonal information
Responsible Party: Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT04606381    
Other Study ID Numbers: CR108891
2020-003225-36 ( EudraCT Number )
61186372NSC1003 ( Other Identifier: Janssen Research & Development, LLC )
First Posted: October 28, 2020    Key Record Dates
Last Update Posted: May 6, 2023
Last Verified: May 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
URL: https://www.janssen.com/clinical-trials/transparency

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Janssen Research & Development, LLC:
Additional relevant MeSH terms:
Layout table for MeSH terms
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action